NZ617351B2 - Amorphous solid salts of cobicistat (gs-9350) - Google Patents

Amorphous solid salts of cobicistat (gs-9350) Download PDF

Info

Publication number
NZ617351B2
NZ617351B2 NZ617351A NZ61735112A NZ617351B2 NZ 617351 B2 NZ617351 B2 NZ 617351B2 NZ 617351 A NZ617351 A NZ 617351A NZ 61735112 A NZ61735112 A NZ 61735112A NZ 617351 B2 NZ617351 B2 NZ 617351B2
Authority
NZ
New Zealand
Prior art keywords
amorphous solid
compound
salt
formula
solid
Prior art date
Application number
NZ617351A
Other versions
NZ617351A (en
Inventor
Joanna M Koziara
Anne Luong
Keiko Sujino
Richard Yu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority claimed from PCT/US2012/035871 external-priority patent/WO2012151165A1/en
Publication of NZ617351A publication Critical patent/NZ617351A/en
Publication of NZ617351B2 publication Critical patent/NZ617351B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Abstract

Disclosed is the amorphous solid of a compound of formula (I), optionally in the form of its pharmaceutically acceptable salts. Further disclosed are methods for preparing the above compound, pharmaceutical compositions which comprise the above compound with additional therapeutic agents, the use of the above compound for the preparation of a medicament for administration to a patient to improve the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, and for the treatment of HIV infection. The chemical name of the amorphous solid of a compound of formula (I) is: ((thiazol-5-yl)methyl) (2R,5R)-5-(((S)-(3-((isopropylthiazol-4-yl)methyl)-3-methylureido)-2-(morpholinoethyl)ethyl)amido)-1,6-diphenylhexan-2-ylcarbamate the above compound for the preparation of a medicament for administration to a patient to improve the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, and for the treatment of HIV infection. The chemical name of the amorphous solid of a compound of formula (I) is: ((thiazol-5-yl)methyl) (2R,5R)-5-(((S)-(3-((isopropylthiazol-4-yl)methyl)-3-methylureido)-2-(morpholinoethyl)ethyl)amido)-1,6-diphenylhexan-2-ylcarbamate

Description

AMORPHOUS SOLID SALTS OF COBICISTAT (GS-9350) Background of the Invention International patent application publication number describes compounds and pharmaceutical compositions that improve the pharmacokinetics of a co- administered drug by inhibiting cytochrome P450 monooxygenase. One such inhibitor is the compound of formula (I).
S N S N N N O Unfortunately, the solid state properties of the compound of formula (I) make it difficult to handle and process on a large scale. For example, its low glass transition temperature, hygroscopicity, and lack of crystallinity, as well as its non free-flowing nature make it particularly difficult to process and to formulate (e.g. as a tablet).
International patent application publication number ,179 discusses the difficulties associated with processing the compound of formula (I) and describes combining the compound of formula (I) with solid carrier particles to improve the physical properties of the resulting solid material. Although the resulting free-flowing powder has high loading values for the compound of formula (I), acceptable physical and chemical stability, rapid drug release properties, and excellent compressibility, the inert carrier particles contribute to the overall weight and volume of the solid so that significantly more material is required in a formulation to achieve a given dose of the compound of formula (I). Accordingly, there is a need for solid forms of the compound of formula (I) that have the beneficial properties of the solids described in ,179, but lack the inert carrier particles that contribute to the weight and the volume of the solid.
Summary of the Invention The invention provides solid amorphous forms of the compound of formula (I) that have many of the beneficial properties of the materials discussed in international patent application publication number ,179, but lack the inert carrier particles.
Accordingly, in one embodiment, the invention provides an amorphous solid of the invention which is an amorphous solid of a compound of formula (I): N N N O or of a salt thereof.
In another embodiment, the invention provides an amorphous solid of a salt of a compound of formula (I): N N N O that is not coated on a silica particle.
In another embodiment the invention provides a pharmaceutical composition comprising an amorphous solid of the invention.
In another embodiment the invention provides a tablet comprising an amorphous solid of the invention.
In another embodiment the invention provides a pharmaceutical composition comprising an amorphous solid of the invention; tenofovir disoproxil fumarate; emtricitabine; and elvitegravir. - 2A - In another embodiment the invention provides a method to inhibit the activity of cytochrome P-450 in an animal comprising administering an amorphous solid of the invention or a pharmaceutical composition of the invention to the animal (e.g. a mammal such as a human).
In another embodiment the invention provides a method for treating an HIV infection comprising administering to a patient in need thereof a therapeutically effective amount of an amorphous solid of the invention, in combination with a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.
In another embodiment the invention provides an amorphous solid of the invention for use in medical therapy.
In another embodiment the invention provides the use of an amorphous solid of the invention for the prophylactic or therapeutic treatment of an HIV infection.
In another embodiment the invention provides the use of an amorphous solid of the invention for inhibiting the activity of cytochrome P-450.
In another embodiment the invention provides an amorphous solid of the invention for use in the preparation of a medicament for treating HIV infection in a mammal.
In another embodiment the invention provides an amorphous solid of the invention for use in the preparation of a medicament for inhibiting the activity of cytochrome P-450 in an animal.
In another embodiment the invention provides a method comprising: a) contacting a compound of formula (I) with a requisite acid in a first solvent, and b) adding a second solvent under conditions that allow a salt to form.
In another embodiment the invention provides a method comprising, spray drying a solution comprising a compound of formula (I) and a requisite acid under conditions that allow a salt to form.
In another embodiment the invention provides a method comprising adding a toluene solution of a compound formula (I): to heptanes to provide an amorphous solid.
In another embodiment the invention provides a method for preparing a pharmaceutical composition comprising combining the amorphous solid of the invention and a pharmaceutically acceptable excipient to provide the pharmaceutical composition.
In another embodiment the invention provides a method for preparing a pharmaceutical composition comprising: combining an amorphous solid of the invention, tenofovir disoproxil fumarate, emtricitabine, and elvitegravir to provide the pharmaceutical composition.
In another embodiment the invention provides a material prepared by a method described herein.
Brief Description of the Drawings Figure 1: the X-ray powder diffraction (XRPD) pattern of Compound 1.
Figure 2: the XRPD pattern of the citrate salt of Compound 1 showing contamination with crystalline citric acid.
Figure 3: the XRPD pattern of the citrate salt of Compound 1.
Figure 4: the XRPD pattern of the tartrate salt of Compound 1.
Figure 5: the XRPD pattern of the oxalate salt of Compound 1.
Figure 6: the XRPD pattern of the fumarate salt of Compound 1.
Figure 7: the XRPD pattern of the hydrochloride salt of Compound 1.
Figure 8: XRPD pattern of the lactate salt of Compound 1.
Figure 9: XRPD pattern of the phosphate salt of Compound 1.
Figure 10: XRPD pattern of the sulfate salt of Compound 1.
Figure 11: XRPD pattern of the malate salt of Compound 1.
Detailed Description of the Invention It will be appreciated by those skilled in the art that compounds of formula (I) may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of formula (I), which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase. - 4A - An “amorphous solid” as used herein includes solid materials that do not have a periodical three-dimensional pattern". For example, amorphous solids that lack crystallinity can be identified by XRPD analysis as illustrated herein. In one embodiment an amorphous solid is a free flowing, handible form (e.g. powder or solid). In another embodiment an amorphous solids excludes glassy, rubbery, and gum like materials including the formula I materials prepard in International Patent Application Publication Number .
In one embodiment the invention provides pharmaceutical compositions comprising an amorphous solid of the invention that can be administered to a mammalian host, such as a human patient, in a variety of forms adapted to the chosen route of administration (e.g. orally).
The compositions of the invention may include one or more pharmaceutically acceptable excipients. Excipients include but are not limited to substances that can serve as a vehicle or medium for an amorphous solid of the invention (e.g. a diluent or a carrier).
They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations will typically contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain the following: binders such as hydroxypropyl cellulose, povidone, or hydroxypropyl methylcellulose; fillers, such as microcrystalline cellulose, pregelatinized starch, starch, mannitol, or lactose monohydrate; a disintegrating agent such as croscarmellose sodium, cross-linked povidone, or sodium starch glycolate; a lubricant such as magnesium stearate, stearic acid, or other metallic stearates; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form.
For instance, tablets, pills, or capsules may be coated with gelatin, polymers, wax, shellac or sugar and the like. Of course, any material used in preparing any unit dosage form will typically be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the compositions of the invention may be incorporated into sustained- release preparations and devices.
The compositions of the invention can also be administered topically, e.g., transdermally, buccally, or sublingually. Accordingly, the invention also provides pharmaceutical compositions that are formulated for such routes of topical administration.
Useful dosages of the compounds of formula (I) can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art.
The amount of a composition of the invention required for use in treatment will vaiy with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
In general, however, a suitable dose of the compound of formula (I) will be in the range of from about 0.05 to about 100 mg/kg, e.g., from about 0.05 to about 50 mg/kg of body weight per day, preferably in the range of 0.05 to 10 mg/kg/day, most preferably in the range of 0.05 to 5 mg/kg/day.
The compound is conveniently formulated in unit dosage form; for example, containing about 5 to 500 mg, about 5 to 250 mg, or about 10 to 100 mg of the compound of formula (I). In one embodiment, the invention provides a composition comprising about 5, about 25, or about 100 mg of a compound of formula (I) formulated in a unit dosage, and one or more pharmaceutically acceptable excipients.
The ability of a compound of formula (I) to inhibit cytochrome P-450 can be evaluated as described in international patent application publication number .
Combination Formulations As discussed in international patent application publication number , the compound of formula (I) improves the pharmacokinetics of a co-administered drug, e.g., by inhibiting cytochrome P-450 monooxygenase. Accordingly, in another embodiment, the pharmaceutical compositions of the invention can further comprise at least one additional therapeutic agent.
The additional therapeutic agent can be any agent having a therapeutic effect when used in combination with the compound of the present invention. For example, the additional therapeutic agent used in combination with the compound of formula (I) can be any agent that is accessible to oxidative metabolism by cytochrome P450 enzymes, especially cytochrome P450 monooxygenase, e.g., 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2E1, 3A4, 5, 7, etc.
In one example, the additional therapeutic agent can be any anti-viral agent, e.g., anti- HIV, anti-HCV, etc., anti-bacterial agent, anti-fungal agent, immuno-modulator, e.g., immunosuppressant, anti-neoplastic agent, chemotherapeutic agent, agents useful for treating cardiovascular conditions, neurological conditions, etc. In another example, the additional therapeutic agent can be any proton pump inhibitor, anti-epileptics, NSAID, oral hypoglycemic agent, angiotensin II receptor antagonist, sulfonylurea, beta blocker, antidepressant, antipsychotic, or anesthetic, or a combination thereof.
In another example, the additional therapeutic agent can be any 1) macrolide antibiotic, e.g., clarithromycin, erythromycin, telithromycin, 2) anti-arrhythmic, e.g., quinidine=>3-OH, 3) benzodiazepine, e.g., alprazolam, diazepam=>3-OH, midazolam, triazolam, 4) immune modulator, e.g., cyclosporine, tacrolimus (FK506), 5) HIV antiviral, e.g., indinavir, nelfmavir, ritonavir, saquinavir, 6) prokinetic, e.g., cisapride, 7) antihistamine, e.g., astemizole, chlorpheniramine, terfenidine, 8) calcium channel blocker, e.g., amlodipine, diltiazem, felodipine, lercanidipine, nifedipine, nisoldipine, nitrendipine, verapamil, 9) HMG CoA reductase inhibitor, e.g., atorvastatin, cerivastatin, lovastatin, simvastatin, or 10) steroid 6beta-OH, e.g., estradiol, hydrocortisone, progesterone, testosterone.
In another example, the additional therapeutic agent can be alfentanyl, aprepitant, aripiprazole, buspirone, cafergot, caffeine, TMU, cilostazol, cocaine, codeine- N- demethylation, dapsone, dextromethorphan, docetaxel, domperidone, eplerenone, fentanyl, finasteride, gleevec, haloperidol, irinotecan, LAAM, lidocaine, methadone, nateglinide, ondansetron, pimozide, propranolol, quetiapine, quinine, salmeterol, sildenafil, sirolimus, tamoxifen, paclitaxel, terfenadine, trazodone, vincristine, zaleplon, or Zolpidem or a combination thereof.
In one specific embodiment, the invention provides a pharmaceutical composition comprising, 1) an amorphous solid of the invention, 2) at least one additional therapeutic agent selected from the group consisting of HIV protease inhibiting compounds, HIV non- nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, non-nucleoside inhibitors of HCV, CCR5 inhibitors, and combinations thereof, and 3) a pharmaceutically acceptable excipient.
In another embodiment, the present invention provides pharmaceutical compositions comprising 1) an amorphous solid of the invention, 2) at least one additional therapeutic agent selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC- 114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC- 681, DPC-684, GW640385X, DG17, PPL-100, DG35, AG 1859, capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+)-calanolide A, etravirine, GW5634, DPC-083, DPC- 961, DPC-963, MIV-150, TMC-120, TMC-278 (rilpivirine), BILR 355 BS, VRX 840773, UK-453061, RDEA806, zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, Racivir (±-FTC), D- d4FC, phosphazide, fozivudine tidoxil, apricitibine AVX754, amdoxovir, KP-1461, and fosalvudine tidoxil (formerly HDP 99.0003), tenofovir disoproxil fumarate, adefovir dipivoxil, GS-9131, curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), elvitegravir, BMS- 538158, GSK364735C, BMS-707035, MK-2048, BA 0 11, enfuvirtide, sifuvirtide, FB006M, TRI-1 144, AMD-070, SP01A, BMS-488043, BlockAide/ CR, immunitin, benzimidazole derivatives, benzo-l,2,4-thiadiazine derivatives, phenylalanine derivatives, aplaviroc, vicriviroc, and maraviroc, cyclosporine, FK-506, rapamycin, paclitaxel, taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM- 450, BILA 201 1 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629 (N,N-dimethylglycyl-N-(2-hydroxy-3 -(((4-methoxyphenyl)sulphonyl)(2- methylpropyl)amino)-l -(phenylmethyl)propyl)methyl-L-valinamide), KNI-272, CGP 53437, CGP 57813 and U-103017; and 3) a pharmaceutically acceptable excipient.
In another embodiment, the present invention provides pharmaceutical compositions comprising, 1) an amorphous solid of the invention, and 2) two or three additional therapeutic agents. For example, additional therapeutic agents selected from the classes of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and HIV integrase inhibitors. The two or three additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, or they can be selected from different classes of therapeutic agents.
In another embodiment, the invention provides pharmaceutical compositions that comprise a ternary combination of agents selected from an amorphous solid of the invention,/tenofovir disoproxil fumarate/emtricitabine, an amorphous solid of the invention/tenofovir disoproxil fumarate/elvitegravir, an amorphous solid of the invention/tenofovir disoproxil fumarate/efavrenz, an amorphous solid of the invention/tenofovir disoproxil fumarate/atazanavir, an amorphous solid of the invention/tenofovir disoproxil fumarate/darunavir, an amorphous solid of the invention/tenofovir disoproxil fumarate/raltegravir, an amorphous solid of the invention/tenofovir disoproxil fumarate/rilpivirine, an amorphous solid of the invention/emtricitabine/elvitegravir, an amorphous solid of the invention/emtricitabine/efavrenz, an amorphous solid of the invention/emtricitabine/atazanavir, an amorphous solid of the invention/emtricitabine/damnavir, an amorphous solid of the invention/emtricitabine/raltegravir, an amorphous solid of the invention/emtricitabine/rilpivirine, an amorphous solid of the invention/elvitegravir/efavrenz, an amorphous solid of the invention/elvitegravir/atazanavir, an amorphous solid of the invention/elvitegravir/darunavir, an amorphous solid of the invention/elvitegravir/raltegravir, an amorphous solid of the invention/elvitegravir/rilpivirine, an amorphous solid of the invention/efavrenz/atazanavir, an amorphous solid of the invention/efavrenz/darunavir, an amorphous solid of the invention/efavrenz/raltegravir, an amorphous solid of the invention/efavrenz/rilpivirine, an amorphous solid of the invention/atazanavir/darunavir, an amorphous solid of the invention/atazanavir/raltegravir, an amorphous solid of the invention/atazanavir/rilpivirine, an amorphous solid of the invention/darunavir/raltegravir, an amorphous solid of the invention/darunavir/rilpivirine, and an amorphous solid of the invention/raltegravir/rilpivirine.
In another embodiment, the invention provides pharmaceutical compositions that comprise a quaternary combination of agents selected from an amorphous solid of the invention/tenofovir disoproxil fumarate/emtricitabine/elvitegravir, an amorphous solid of the invention/tenofovir disoproxil fumarate/emtricitabine/efavrenz, an amorphous solid of the invention/tenofovir disoproxil fumarate/emtricitabine/atazanavir, an amorphous solid of the invention/tenofovir disoproxil fumarate/emtricitabine/darunavir, an amorphous solid of the invention/tenofovir disoproxil fumarate/emtricitabine/raltegravir, an amorphous solid of the invention/tenofovir disoproxil fumarate/emtricitabine/rilpivirine, an amorphous solid of the invention/tenofovir disoproxil fumarate/elvitegravir/efavrenz, an amorphous solid of the invention/tenofovir disoproxil fumarate/elvitegravir/atazanavir, an amorphous solid of the invention/tenofovir disoproxil fumarate/elvitegravir/darunavir, an amorphous solid of the invention/tenofovir disoproxil fumarate/elvitegravir/raltegravir, an amorphous solid of the invention/tenofovir disoproxil fumarate/elvitegravir/rilpivirine, an amorphous solid of the invention/tenofovir disoproxil fumarate/efavrenz/atazanavir, an amorphous solid of the invention/tenofovir disoproxil fumarate/efavrenz/darunavir, an amorphous solid of the invention/tenofovir disoproxil fumarate/efavrenz/raltegravir, an amorphous solid of the invention/tenofovir disoproxil fumarate/efavrenz/rilpivirine, an amorphous solid of the invention/tenofovir disoproxil fumarate/atazanavir/daranavir, an amorphous solid of the invention/tenofovir disoproxil fumarate/atazanavir/raltegravir, an amorphous solid of the invention/tenofovir disoproxil fumarate/atazanavir/rilpivirine, an amorphous solid of the invention/tenofovir disoproxil fumarate/daranavir/raltegravir, an amorphous solid of the invention/tenofovir disoproxil fumarate/darunavir/rilpivirine, an amorphous solid of the invention/tenofovir disoproxil fumarate/raltegravir/rilpivirine, an amorphous solid of the invention/GS-9131/emtricitabine/elvitegravir, an amorphous solid of the invention/emtricitabine/elvitegravir/efavrenz, an amorphous solid of the invention/emtricitabine/elvitegravir/atazanavir, an amorphous solid of the invention/emtricitabine/elvitegravir/darunavir, an amorphous solid of the invention/emtrieitabine/elvitegravir/raltegravir, an amorphous solid of the invention/emtricitabine/elvitegravir/rilpivirine, an amorphous solid of the invention/emtricitabine/efavrenz/atazanavir, an amorphous solid of the invention/emtricitabine/efavrenz/darunavir, an amorphous solid of the invention/emtricitabine/efavrenz/raltegravir, an amorphous solid of the invention/emtricitabine/efavrenz/rilpivirine, an amorphous solid of the invention/emtricitabine/atazanavir/darunavir, an amorphous solid of the invention/emtricitabine/atazanavir/raltegravir, an amorphous solid of the invention/emtricitabine/atazanavir/rilpivirine, an amorphous solid of the invention/emtricitabine/darunavir/raltegravir, an amorphous solid of the invention/emtricitabine/darunavir/rilpivirine, an amorphous solid of the invention/emtricitabine/raltegravir/rilpivirine, an amorphous solid of the invention/elvitegravir/efavrenz/atazanavir, an amorphous solid of the invention/elvitegravir/efavrenz/darunavir, an amorphous solid of the invention/elvitegravir/efavrenz/raltegravir, an amorphous solid of the invention/el vitegravir/efavrenz/rilpivirine, an amorphous solid of the invention/el vitegravir/atazanavir/darunavir, an amorphous solid of the invention/elvitegravir/atazanavir/raltegravir, an amorphous solid of the invention/elvitegravir/atazanavir/rilpivirine, an amorphous solid of the invention/elvitegravir/darunavir/raltegravir, an amorphous solid of the invention/elvitegravir/darunavir/rilpivirine, an amorphous solid of the invention/elvitegravir/raltegravir/rilpivirine, an amorphous solid of the invention/efavrenz/atazanavir/darunavir, an amorphous solid of the invention/efavrenz/atazanavir/raltegravir, an amorphous solid of the invention/efavrenz/atazanavir/rilpivirine, an amorphous solid of the invention/efavrenz/darunavir/raltegravir, an amorphous solid of the invention/efavrenz/darunavir/rilpivirine, an amorphous solid of the invention/efavrenz/raltegravir/rilpivirine, an amorphous solid of the invention/atazanavir/darunavir/raltegravir, an amorphous solid of the invention/atazanavir/darunavir/rilpivirine, and an amorphous solid of the invention/darunavir/raltegravir/rilpivirine.
Combination Methods of Treatment In one embodiment, the compositions of the invention that comprise an amorphous solid of the invention can be used alone, e.g., for inhibiting cytochrome P450 monooxygenase. In another embodiment, the compositions of the invention can be used in combination with other active therapeutic ingredients or agents. Preferably, the other active therapeutic ingredients or agents are metabolized or accessible to the oxidative metabolism by cytochrome P450 enzymes, e.g., monooxygenase enzymes such as 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2E1, 3A4, 5, 7, etc., thereby reducing the amount or rate at which the other active therapeutic agent or ingredient is metabolized, whereby the pharmacokinetics of the other active therapeutic agent or ingredient is improved. Such improvements can include elevating the blood plasma levels of the other therapeutic agent or ingredient or maintaining a more therapeutically effective blood plasma level of the other therapeutic active agent or ingredient compared to blood plasma levels of the other therapeutic agent or ingredient administered without the compositions of the invention that comprise an amorphous solid of the invention.
Co-administration of an amorphous solid of the invention with one or more other active therapeutic agents generally refers to simultaneous or sequential administration of the amorphous solid of the invention and one or more other active therapeutic agents, such that therapeutically effective amounts of the amorphous solid of the invention and one or more other active therapeutic agents are both present in the body of the patient.
Co-administration includes administration of unit dosages of the amorphous solid of the invention before or after administration of unit dosages of one or more other active therapeutic agents, for example, administration of the amorphous solid of the invention within seconds, minutes, or hours of the administration of one or more other active therapeutic agents. For example, a unit dose of a compound of an amorphous solid of the invention can be administered first, followed within seconds or minutes by administration of a unit dose of one or more other active therapeutic agents. Alternatively, a unit dose of one or more other therapeutic agents can be administered first, followed by administration of a unit dose of amorphous solid of the invention within seconds or minutes. In some cases, it may be desirable to administer a unit dose of an amorphous solid of the invention first, followed, after a period of hours (e.g., 1 to 12 hours), by administration of a unit dose of one or more other active therapeutic agents. In other cases, it may be desirable to administer a unit dose of one or more other active therapeutic agents first, followed, after a period of hours (e.g., 1 to 12 hours), by administration of a unit dose of an amorphous solid of the invention.
In yet another embodiment, the present invention provides a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a composition of the invention that comprise an amorphous solid of the invention.
In yet another embodiment, the present application provides a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a therapeutically effective amount of a composition of the invention that comprise an amorphous solid of the invention.
In yet another embodiment, the present application provides a method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase 3A, comprising administering to a patient treated with said drug, a composition of the invention that comprise an amorphous solid of the invention.
In yet another embodiment, the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with said drug, a composition of the invention that comprise an amorphous solid of the invention.
In yet another embodiment, the present application provides a method for increasing blood plasma levels of a drug which is metabolized by cytochrome P450 monooxygenase 3A, comprising administering to a patient treated with said drug, a composition of the invention that comprise an amorphous solid of the invention.
In yet another embodiment, the present application provides a method for inhibiting cytochrome P450 monooxygenase 3A in a patient comprising administering to a patient in need thereof an amount of a composition of the invention that comprises an amorphous solid of the invention, effective to inhibit cytochrome P450 monooxygenase 3A.
In yet another embodiment, the present application provides a method for treating an HIV infection comprising administering to a patient in need thereof a therapeutically effective amount of a composition of the invention that comprise an amorphous solid of the invention, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non- nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, and CCR5 inhibitors.
In yet another embodiment, the present application provides a method for treating an HIV infection comprising administering to a patient in need thereof a therapeutically effective amount of a composition of the invention that comprise an amorphous solid of the invention, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC- 114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC- 681, DPC-684, and GW640385X, DG17, PPL-100, DG35, AG 1859, capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A, etravirine, GW5634, DPC-083, DPC- 961, DPC-963, MIV-150, TMC-120, TMC-278 (rilpivirine), efavirenz, BILR 355 BS, VRX 840773, UK-453061, RDEA806, zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±- FTC), D-d4FC, emtricitabine, phosphazide, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461, fosalvudine tidoxil (formerly HDP 99.0003), tenofovir disoproxil fumarate, adefovir dipivoxil, curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), elvitegravir, BMS-538158, GSK364735C, BMS-707035, MK-2048, and BA 011, enfuvirtide, sifuvirtide, FB006M, and TRI-1144, AMD-070, an entry inhibitor, SP01A, BMS-488043, BlockAide/ CR, a G6PD and NADH-oxidase inhibitor, immunitin, aplaviroc, vicriviroc, maraviroc, PRO- 140, INCB 15050, PF-232798 (Pfizer), CCR5mAb004, BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-1 12, VGV-1, PA-457 (bevirimat), Ampligen, HRG214, Cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889, and PA- 1050040 (PA-040).
In yet another embodiment, the present application provides a method for treating an HCV infection comprising administering to a patient in need thereof a therapeutically effective amount of a composition of the invention that comprise an amorphous solid of the invention, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN alpha (infergen), reaferon, intermax alpha, r-IFN-beta, infergen + actimmune, IFN-omega with DUROS, locteron, albuferon, rebif, Oral interferon alpha, IFNalpha-2b XL, AVI-005, PEG-Infergen, and pegylated IFN-beta, rebetol, copegus, viramidine (taribavirin), NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554, GSK625433, SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339, ITMN-191, MX-3253 (celgosivir), UT-231B, IDN-6556, ME 3738, LB-84451, MitoQ, benzimidazole derivatives, benzo-l,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831, A-689, zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI- 5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM81 1, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, Bavituximab, Oglufanide, and VX-497 (merimepodib).
Specific embodiments of the invention Specific embodiments identified herein are for illustration; they do not in any way exclude other embodiments of the invention.
In one embodiment of the invention the amorphous solid of the compound of formula (I) is a salt.
In one embodiment of the invention the amorphous solid of the compound of formula (I) is a spray dried foam that is not a salt.
In one embodiment of the invention the amorphous solid of the compound of formula (I) is isolated by precipitation from a solution.
In one embodiment of the invention, the compound of formula (I) is enriched with a stereoisomer of formula (la): which is (3i?,6i?,95)methyl[2-(l-methylethyl)thiazolyl][2- (4- morpholinyl)ethyl]-8,l l-dioxo-3,6-bis(phenylmethyl)-2,7,10,12-tetraazatridecanoic acid, 5- thiazolylmethyl ester. The compound of formula (la) is referred to in the Examples herein below as Compound 1. In one embodiment the compound of formula (I) has an enriched concentration of 85 ± 5% of the stereoisomer of formula (la). In another embodiment the compound of formula (I) has an enriched concentration of 90 ± 5% of the stereoisomer of formula (la). In another embodiment the compound of formula (I) has an enriched concentration of 95 ± 2% of the stereoisomer of formula (la). In another embodiment the compound of formula (I) has an enriched concentration of 99 ± 1% of the stereoisomer of formula (la). In another embodiment the compound of formula (I) is the pure the stereoisomer of formula (la).
In one embodiment the invention provides an amorphous solid of a compound of formula I or a salt thereof that is not coated on a filmed silica particle (i.e. coated in the pores or on the surface of a fumed silica particle).
In one embodiment the invention provides an amorphous solid of a compound of formula I or a salt thereof that is not coated on a silica particle.
In one embodiment the invention provides an amorphous solid of a compound of formula I or a salt thereof that is not coated on a solid carrier (e.g. kaolin, bentonite, hectorite, colloidal magnesium-aluminum silicate, silicon dioxide, magnesium trisilicate, aluminum hydroxide, magnesium hydroxide, magnesium oxide and talc).
In one embodiment the invention provides an amorphous solid of a compound of formula I or a salt thereof that is not coated on a solid carrier as described in international patent application publication number ,179.
The invention will now be illustrated by the following non-limiting Examples.
Examples Example 1. Preparation of a Representative Composition of the Invention Compound 1 (3.4 g, 4.38 mmol) was dissolved in toluene (12.2 g). The solution was charged to heptanes (122 g) maintaining about 5 °C. The resulting slurry was agitated at about 5 °C, then filtered. Solids were rinsed forward with heptanes, then dried under vacuum at ambient temperature. Dry product was obtained as an off-white solid (2.77 g, 3.57 mmol, 81% yield, 98.0% AN by HPLC). H NMR (400 MHz, DMSO-d ) δ = 1.30 (d, J = 6.8 Hz, 6H), 1.33–1.42 (m, 4H), 1.57–1.65 (m, 1 H), 1.70–1.79 (m, 1H), 2.13–2.35 (m, 6H), 2.60 (d, J = 6.8, 2H), 2.65 (t, J = 6.4, 2H), 2.89 (s, 3H), 3.23 (ddd, J = 6.8, 6.8, 14, 1H), 3.50 (t, J = 4 Hx, 4H), 3.58–3.68 (m, 1H), 3.88–3.90 (m, 1H), 4.08 (dd, J = 7.2, 12.8 Hz, 1H), 4.47 (s, 2H), 5.17 (s, 2H), 6.61 (d, J = 7.6 Hz, 1H), 7.08–7.23 (m, 12H), 7.51 (d, J = 8.8 Hz, 1H), 9.08 (s, 1H). The XRPD pattern of Compound 1 is shown in Figure 1.
Example 2. Preparation of a Representative Citric Acid Salt of the Invention S Acid (X-H) N N N O N N N O Ph N Solvent GS-9350 GS-9350 salt C H N O S 40 53 7 5 2 Mol. Wt.: 776.02 Citric acid (0.5 g, 2 equiv.) was dissolved in isopropyl acetate (15 g) at reflux.
Compound 1 (1 g, 1.29 mmol, 1 equiv.) was charged and the mixture was heated to reflux for about 15 minutes. The solution was adjusted to ambient. Heptanes (15 g) were charged to precipitate the salt. The product was filtered, rinsed forward with heptanes and dried under vacuum at 40 °C to give an off-white solid (1.43 g, 0.97 mmol, 75% yield, 94.1% AN by HPLC). H NMR (400 MHz, DMSO-d ) δ = 1.30 (d, J = 7.2 Hz, 6H), 1.32–1.47 (m, 4H), 1.62–1.72 (m, 1 H), 1.75–1.87 (m, 1H), 2.30–2.66 (m, 10H), 2.66 (dd, 4H, J = .2, 38.3 Hz)*, 2.89 (s, 3H), 3.20-3.27 (m, 1H), 3.53–3.68 (m, 4H), 3.88–3.99 (m, 1H), 4.08–4.13 (m, 1H), 4.47 (s, 2H), 5.16 (s, 2H), 6.60 (d, J = 7.2, 1H), 7.09–7.23 (m, 12H), 7.56 (d, J = 8.8, 1H), 7.87 (s, 1 H), 9.08 (s, 1H). As shown in Figure 2, the product (top line) was contaminated with crystalline citric acid (lower line). *citrate, 3.6 equiv.
Example 3. Preparation of a Representative Citric Acid Salt of the Invention A solution of Compound 1 (2 g, 2.58 mmol) and citric acid (0.4 g, 0.21 mmol, 0.8 equiv.) in dichloromethane (10.5 g) was charged to methyl tert-butylether (182 g) drop wise at ambient temperature. The resultant slurry was agitated at ambient temperature.
Solids were filtered and dried under vacuum at ~ 40 °C to yield white solids (1.64 g, 1.69 mmol, 66% yield, 93.3% AN by HPLC). H NMR (400 MHz, DMSO-d ) δ = 1.30 (d, J = 7.2 Hz, 6H), 1.32–1.47 (m, 4H), 1.62–1.72 (m, 1 H), 1.75–1.87 (m, 1H), 2.30–2.66 (m, 10H), 2.66 (dd, 4H, J = 15.2, 38.3 Hz)*, 2.89 (s, 3H), 3.20–3.27 (m, 1H), 3.53–3.68 (m, 4H), 3.88–3.99 (m, 1H), 4.08–4.13 (m, 1H), 4.47 (s, 2H), 5.16 (s, 2H), 6.60 (d, J = 7.2, 1H), 7.09–7.23 (m, 12H), 7.56 (d, J = 8.8, 1H), 7.87 (s, 1H), 9.08 (s, 1H). The XRPD pattern of the citrate salt of Compound 1 is shown in Figure 3. *citrate, 1 equiv.
Example 4. Preparation of a Representative Tartrate Salt of the Invention A mixture of Compound 1 (1.25 g, 1 equiv.) and L-tartaric acid (0.5 g, 2 equiv.) in isopropyl alcohol (3.9 g) was agitated at about 45 °C for about 15 minutes. The resultant solution was adjusted to ambient temperature, then methyl tert-butylether (45 g) was charged to yield a slurry. The product was filtered, rinsed forward with heptanes and dried under vacuum at 40 °C to give an off-white solid (quantitative yield, 95.5% AN). H NMR (400 MHz, DMSO-d ) δ = 1.30 (d, J = 7.2, 6H), 1.32–1.47 (m, 4H), 1.63–1.70 (m, 1H), 1.75–1.82 (m, 1H), 2.24–2.52 (m, 6H), 2.60–2.72 (m, 4H), 2.89 (s, 3H), 3.18-3.28 (m, 1H), 3.53–3.68 (m, 4H), 3.88–3.99 (m, 1H), 4.07–4.12 (m, 1H), 4.28 (s, 2H)*, 4.47 (s, 2H), 5.16 (s, 2H), 6.61 (d, J = 7.2, 1H), 7.09–7.23 (m, 12H), 7.55 (d, J = 8.8, 1H), 7.87 (s, 1H), 9.08 (s, 1H). * tartrate, 2 equiv. The XRPD pattern of the tartrate salt of Compound 1 is shown in Figure 4.
Example 5. Preparation of a Representative Oxalate Salt of the Invention To a solution of oxalic acid (0.28 g, 3.22 mmol, 2.4 equiv.) in isopropyl acetate (11 g) at ambient temperature, a solution of Compound 1 (1 g, 1.29 mmol, 1.0 equiv.) in isopropyl acetate (3 g) was charged drop-wise at ambient temperature followed by heptane (10 g). The resultant slurry was agitated at ambient temperature for about 30 minutes The product was filtered and rinsed forward with heptanes and dried under vacuum at 40 °C to give a light yellow solid (1.27 g, 99% yield, 95.4% AN by HPLC). H NMR: (400 MHz, DMSO-d ) δ = 1.30 (d, J = 7.2 Hx, 6H), 1.30–1.50 (m, 4H), 1.85–1.95 (m, 1H), 1.95–2.05 (m, 1H), 2.62–2.67 (m, 4H), 2.93 (s, 3H), 2.95–3.01 (m, 2H), 4.07–3.20 (m, 4H), 3.20– 2.37 (m, 1H), 3.60–3.70 (m, 1H), 3.75–3.89 (m, 4H), 3.90–3.98 (m, 1H), 4.50 (dd, J = 16.4, 22.4 Hz, 2H), 5.17 (s, 2H), 6.57 (d, J = 7.2 Hz, 1H), 7.05–7.25 (m, 12H), 7.71 (d, J = 8.4 Hz, 1H), 7.87 (s, 1H), 9.08 (s, 1H). Oxalate (2 eqiv based on the mole ratio of input acid). The XRPD pattern of the oxalate salt of Compound 1 is shown in Figure 5.
Example 6. Preparation of a Representative Fumarate Salt of the Invention Fumaric acid (0.3 g, 2.58 mmol, 2 equiv.) was dissolved in isopropyl alcohol (5 g) at reflux. Compound 1 (1 g, 1.29 mmol, 1 equiv.) was charged. The resulting solution was concentrated under vacuum in a bath set at about 40 °C. Isopropyl acetate (25 g) and heptane (30 g) were charged. The resulting slurry was agitated at ambient temperature for about 30 minutes Solids were filtered and dried under vacuum at 40 °C. An off-white solid was obtained (1.02 g, 1.01 mmol as bis fumarate, 78%, 94.0% AN by HPLC). H NMR (400 MHz, DMSO-d ) δ = 1.3 (d, 6H), 1.3–1.5 (m, 4H), 1.6–1.7 (m, 1H), 1.7–1.8 (m, 1H), 2.2–2.5 (m, 6H), 2.6–2.77 (m, 4H), 2.9 (s, 3H), 3.2–3.3 (m, 1H), 3.5–3.7 (m, 5H), 3.9–4.0 (m, 1H), 4.1–4.2 (m, 1H), 4.5 (s, 2H), 5.2 (s, 2H), 6.6 (m, 1H), 6.6 (S, 2H)*, 7.1–7.3 (m, 12H), 7.6 (d, 1H), 7.9 (s, 1H), 9.1 (s, 1H). *Fumarate, 2 equiv. The XRPD pattern of the fumarate salt of Compound 1 is shown in Figure 6.
Example 7. Preparation of a Representative Hydrochloric Acid Salt of the Invention Compound 1 (8.35 g, 10.8 mmol, 1 equiv.) was dissolved in 1.25 M HCl in ethanol (6.8 mL, HCl 8.5 mmol, 0.8 equiv.) . The resulting solution was charged to methyl tert- butylether (84 g). The resulting mixture was concentrated under vacuum at about 40 °C.
Methyl tert-butylether (80 g) was charged. The mixture was agitated at ambient. The product was filtered, rinsed forward with methyl tert-butylether, then dried under vacuum at about 40 °C, to provide an off-white solid (7.31 g, 9.0 mmol, 83% yield, 96.8% AN).
H NMR (400 MHz, DMSO-d ) δ =1.30 (d, J = 6.8, 6H), 1.33–1.47 (m, 4H), 1.96–2.12 (m, 2H), 2.24–2.52 (m, 6H), 2.61–2.71 (m, 4H), 2.82 (s, 3H), 2.95–3.09 (m, 2H), 3.23 (ddd, J = 6.8, 6.8, 14 Hz, 1H), 3.30–3.40 (m, 4H), 3.60–3.68 (m, 1H), 3.76–3.88 (m, 2H), 3.88–3.98 (m, 3H), 4.16–4.22 (m, 1H), 4.49 (dd, J = 16.4, 22.4 Hz,, 2H), 5.16 (s, 2H), 6.57 (d, J = 6.8 Hz, 1H), 7.09–7.24 (m, 11H), 7.84–7.87 (m, 2H), 9.09 (s, 1H), 11.1 (br, 1H). Titration: hydrochloride, 1 equiv. The XRPD pattern of the hydrochloride salt of Compound 1 is shown in Figure 7.
Example 8. Preparation of a Representative Lactate Salt of the Invention Compound 1 (2.7 g, 3.48 mmol, 1 equiv.) and lactic acid (85% aqueous solution, 0.37 g, 3.49 mmol, 1 equiv. ) were dissolved in ethanol (10.5 g). The resultant solution was concentrated under vacuum, and coevaporated with toluene. The concentrate was dissolved in toluene (9 g), and charged to heptanes at about 5 °C. The resulting slurry was agitated at about 5 °C, then filtered and rinsed forward with heptanes. The product was dried at about 40 °C to afford light brown solid (2.81 g, 3.24 mmol, 93% yield, 97.5% AN). H NMR (400 MHz, DMSO-d ) δ = 1.24 (d, J = 6.8 Hx, 3H)*, 1.30 (d, J = 7.3 Hz, 6H), 1.34–1.41 (m, 4H), 1.62 (dt, J = 6.8, 20.8, 1H), 1.76 (dt, J = 6.6, 20, 1H), 2.15–2.34 (m, 6H), 2.60–2.66 (m, 4H), 2.89 (s, 3H), 3.23 (ddd, J = 7.2, 13.6, 20.8 Hz), 3.51 (t, J = 4.4, 3H), 3.60–3.68 (m, 1H), 3.90–3.98 (m, 1H), 4.04 (dd, J = 6.8, 13.8 Hz, 1H)*, 4.09 (dd, J = 6.8, 12.8 Hz, 1H), 4.47 (s, 2H), 5.17 (s, 2H), 7.07–7.24 (m, 12H), 7.53 (d, J = 8.4 Hz, 1H), 7.87 (s, 1H), 9.08 (s, 1H). * lactate, 1 equiv. The XRPD pattern of the lactate salt of Compound 1 is shown in Figure 8.
Example 9. Preparation of a Representative Phosphate Salt of the Invention Compound 1 (4.70 g, 6.06 mmol, 1 equiv.) and H PO (0.72 g, 85%, 6.24 mmol, 1 equiv.) was dissolved in isopropyl alcohol (10 g) at about 40 °C. The mixture was adjusted to ambient temperature. Heptanes (80 g) were charged. The resulting slurry was agitated at ambient. The product was filtered and rinsed forward with heptanes, then dried under vacuum at about 40 °C to afford a light brown solid (5.2 g, 5.74 mmol, 95% yield). H NMR (400 MHz, DMSO-d ) δ = 1.30 (d, J = 7.2, 6H), 1.35–1.40 (m, 4H), 1.62–1.70 (m, 1H), 1.75–1.83 (m, 1H), 2.26–2.48 (m, 6H), 2.60 (d, J = 6.8 Hz, 2H), 2.65 (t, J = 5.6 Hz, 2H), 2.89 (s, 3 H), 3.23 (ddd, J = 7.2, 7.2, 20.8 Hz, 1H), 3.56 (m, 4H), 3.60–3.67 (m, 1H), 3.88-3.98 (m, 1H), 4.07–4.12 (m, 1H), 4.47 (s, 2H), 5.16 (s, 2H), 6.62 (d, J = 7.4, 1H), 7.10–7.23 (m, 12H), 7.56 (d, J = 8.4, 1H), 7.87 (s, 1H), 9.08 (s, 1H). Titration: phosphate, 1 equiv. The XRPD pattern of the phosphate salt of Compound 1 is shown in Figure 9.
Example 10. Preparation of a Representative Sulfate Salt of the Invention Compound 1 (3.47 g, 4.47 mmol, 1 equiv) and conc. H SO (250 L, 4.46 mmol, 1 equiv.) were dissolved in isopropyl alcohol (10.5 g) at ambient temperature. The mixture was concentrated to dryness under vacuum. The residue was dissolved in a mixture of dimethoxyethane (60 g) and isopropanol (5 g). The solution was charged to methyl tert- butylether (175 g), and the resulting slurry was agitated at ambient. The product was filtered, rinsed forward with methyl tert-butylether and dried under vacuum at 40 °C to give an off-white solid (2.63 g, 3.01 mmol, 67% yield). H NMR (400 MHz, DMSO-d ) δ = 1.30 (d, J = 7.2, 6H), 1.34–1.45 (m, 4H), 1.83–2.02 (m, 1H), 2.64 (dd, J = 6.4 16.0 Hz, 4H), 2.91 (s, 3H), 2.97-3.11 (m, 4H), 3.23 (ddd, J = 6.4, 6.4, 13.6 Hz, 1H), 3.38 (dd, J = 11.6, 22 Hz, 1H), 3.60–3.68 (m, 3H), 3.90–4.00 (m, 3H), 4.18 (dd, J = 8.0, 13,2 Hz, 1H), 4.46 (d, J = 16.4 Hz, 1H), 4.53 (d, J = 16.4 Hz, 1H), 5.17 (s, 2H), 6.54 (d, J = 7.8, 1H), 7.10–7.24 (m, 12H), 7.70 (d, J = 8.4 Hz, 1H), 7.87 (s, 1H), 9.09 (s, 1H), 9.61 (br, 1H).
Titration: sulfate, 1 equiv. The XRPD pattern of the sulfate salt of Compound 1 is shown in Figure 10.
Example 11. Preparation of a Representative Malate Salt of the Invention Compound 1 (2.0 g, 2.58 mmol, 1 equiv.) and (S)-(-) malic acid (348 mg, 2.60 mmol, 1 equiv.) were dissolved in dichloromethane (6.7 g) at ambient temperature. The resulting solution was charged to methyl tert-butylether (75 g). Solids were filtered, and rinsed forward with methyl tert-butylether. The product was dried under vacuum at 40 °C to give an off-white solid (1.28 g, 1.41 mmol, 54% yield, 98.7% AN). H NMR (400 MHz, DMSO-d ) δ = 1.30 (d, J = 7.2, 6H), 1.34–1.41 (m, 4H), 1.64 (ddd, J = 7.2, 7.2, 13.6, 1H), 1.76 (ddd, J = 6.8, 6.8, 13.6 Hz), 2.20–2.45 (m, 7H), 2.55–2.67 (m, 5H), 2.89 (s, 3H), 3.23 (ddd, J = 7.2, 7.2, 14.0 Hz, 1H), 3.54 (t, J = 4.0 Hz, 4H), 3.58–3.68 (m, 1H), 3.90– 3.98 (m, 1H), 4.09 (dd, J = 7.2, 12.8, 1H), 4.21 (dd, J = 5.6, 7.6, 1H)*, 4.47 (s, 2H), 5.16 (s, 2H), 6.61 (d, J = 6.8 Hz, 1H), 7.23–7.09 (m, 12H), 7.54 (d, J = 8.4 Hz, 1H), 7.87 (s, 1H), 9.08 (s, 1H). * malate, 1 equiv. The XRPD pattern of the malate salt of Compound 1 is shown in Figure 11.
Example 12. Determination of Glass Transition Temperatures Glass transition temperatures for the solids prepared in Examples 1-11 are shown in the following table. Modulated differential scanning calorimetry (mDSC) was used to characterize salts of the invention. Solid samples were placed in hermetically sealed aluminum pan with a pinhole. Modulation amplitude of ± 0.8ºC with a period of 60 sec was applied to the sample heated at 2 °C/min under dried nitrogen purge using TA instruments (New Castle, DE, USA) model 1000. Heat-cool-heat cycles were applied to allow for moisture evaporation during first heating cycle and to erase thermal history of the sample, which allowed for the determination of the intrinsic glass transition temperature (Tg) in dry state.
Glass transition temperatures for representative salts of Compound 1 Tg (ºC) Tg (ºC) Salt Form First heating Second heating xinafoate 49 51 gentisate 62 62 phosphate 66 69 sulfate 71 71 citrate 59 60 tosylate 32 46 tartarate 44 66 bromide 68 68 dichloroacetate ND 34 naphtalenesulfate 58 58 camphorosulfonate 66 66 nicotinate 19.6 36 lactate 2 17 hippurate 31 44 ethanesulfonate -0.23 37 malonate 14 36 succinate 16 35 fumarate 37 51 ketoglutarate 24 42 benzoate 14 23 besylate 30 52 edisylate 33 93 saccharinate 37 56 ascorbate 42 60 hydrochloride 34 59 maleate 24 37 oxalate 34 46 Example 13. Determination of Hygroscopic Properties Hygroscopicity of salts of invention were measured by placing 20-50 mg of the sample in an uncapped scintillation vial. The vial was stored at ambient temperature in a Pyrex brand desiccator (VWR, International, CT). The humidity within the desiccator was controlled at 55% RH and 75% RH using saturated aqueous solutions of magnesium nitrite and sodium chloride, respectively. The relative humidity was confirmed using a digital hygrometer pen (VWR International, CT). An empty scintillation vial was also placed in the desiccator as a control. The weight gain for all the samples was determined after 24 hours; it was not determined whether equilibrium was reached after that period.
Visual observation of phase transition was also noted.
Hygroscopicity data for representative salts of compound 1 is provided in the following Table.
Hygroscopicity at room temperature 55% RH 75% RH % weight Phase % weight Phase Salt Form gain transition gain transition xinafoate 0.29 No 1.97 No gentisate 2.17 No 5.2 No phosphate 4.52 No 7.9 Partial sulfate 4.60 Partial 10.3 Yes citrate 3.17 No 6.5 Partial tosylate 3.11 Partial 6.5 Yes tartarate 3.23 No 7.6 Partial bromide 3.24 No 6.0 Yes dichloroacetate 3.36 Yes 7.3 Yes naphtalenesulfate 2.80 No 5.8 Yes camphorosulfonate 2.99 No 5.9 Yes nicotinate 2.07 Yes ND Yes lactate ND ND 5.76 Yes hippurate 3.37 Partial 5.61 Yes ethanesulfonate 8.78 Yes 16.2 Yes malonate 3.43 Yes 6.18 Yes succinate 3.95 Yes 6.09 Yes fumarate 2.11 No 6.02 Yes ketoglutarate 3.27 Yes 5.23 Yes benzoate 1.99 Yes 3.63 Yes besylate 1.83 Partial 6.59 Yes edisylate 6.01 Yes 10.7 Yes saccharinate 1.89 No 4.09 Yes ascorbate 3.23 No 7.56 Yes hydrochloride 4.32 Partial 6.92 Yes maleate 4.41 Yes 6.67 Yes oxalate 4.38 Partial 9.36 Yes Example 14. Preparation of Representative Salts of the Invention A salt of Compound 1 was dissolved in acetone at target concentration of 20% w/w and spry dried using GEA-Niro SDMicro™ Spray Dryer. Solution feeding rate ranged from 3-5 g/ml with atomizing gas pressure of 0.6-1 bar and drying gas rate of approximately 24 kg/hr. Drying gas temperature was maintained at about 45-50 °C and outlet temperature ranged between 40-45 °C.
Glass transition and hygroscopicity of the spray dried salts of the compound of invention are shown below.
Hygroscopicity Weight Weight API Tg (ºC) gain at Phase Phase gain at 75% 55% RH transition transition RH (%) Compound 1 61 3.1 no 5.6 partial gentisate Compound 1 42 2.6 no 3.3 no xinafoate Compound 1 67 5.8 no 6.3 yes tartarate Compound 1 92 4.7 no 8.0 yes phosphate Compound 1 31 3.2 no 6.0 yes fumarate Compound 1 36.4 nd no 4.0 yes saccharinate Compound 1 7.8 partial 9.4 yes chloride Example 15. Representative Formulations of the Invention The following illustrate representative pharmaceutical dosage forms, containing an amorphous solid of the compound of formula I ('Compound X'), for therapeutic or prophylactic use in humans. (i) Tablet 1 mg/tablet Compound X 100.0 Lactose 77.5 Povidone 15.0 Croscarmellose sodium 12.0 Microcrystalline cellulose 92.5 Magnesium stearate 3.0 300.0 (ii) Tablet 2 mg/tablet Compound X 20.0 Microcrystalline cellulose 410.0 Starch 50.0 Sodium starch glycolate 15.0 Magnesium stearate 5.0 500.0 (iii) Capsule mg/capsule Compound X 10.0 Colloidal silicon dioxide 1.5 Lactose 465.5 Pregelatinized starch 120.0 Magnesium stearate 3.0 600.0 (iv) Injection 1 (1 mg/ml) mg/ml Compound X 1.0 Dibasic sodium phosphate 12.0 Monobasic sodium phosphate 0.7 Sodium chloride 4.5 1.0 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad 1 mL (v) Injection 2 (10 mg/ml) mg/ml Compound X 10.0 Monobasic sodium phosphate 0.3 Dibasic sodium phosphate 1.1 Polyethylene glycol 400 200.0 01 N Sodium hydroxide solution (pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad 1 mL (vi) Aerosol mg/can Compound X 20.0 Oleic acid 10.0 Trichloromonofluoromethane 5,000.0 Dichlorodifluoromethane 10,000.0 Dichlorotetrafluoroethane 5,000.0 The above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques.
However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
H:\r ec\In terwoven\ N RPortbl\D CC\R EC\8160692_1. docx-27/08/2015

Claims (5)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1. An amorphous solid of a salt of a compound of formula (I): S N S N N N O that is not coated on a silica particle.
2. The amorphous solid of claim 1 wherein the salt is a citrate, tartrate, oxalate, fumarate, hydrochloride, lactate, phosphate, sulfate, or malate salt.
3. The amorphous solid of claim 1 wherein the salt is a xinafoate, tosylate, bromide, dichloroacetate, naphtalenesulfate, camphorosulfonate, nicotinate, hippurate, ethanesulfonate, malonate, succinate, ketoglutarate, benzoate, besylate, edisylate, saccharinate, ascorbate, or maleate salt.
4. The amorphous solid of any one of claims 1-3 that has a glass transition temperature of at least about 40 ºC.
5. The amorphous solid of any one of claims 1-3 that has a glass transition temperature of at least about 50 ºC. H:\r ec\In terwoven\N RPortbl\ D CC\R EC\8160692_1. docx-27/
NZ617351A 2011-05-02 2012-04-30 Amorphous solid salts of cobicistat (gs-9350) NZ617351B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161481509P 2011-05-02 2011-05-02
US61/481,509 2011-05-02
PCT/US2012/035871 WO2012151165A1 (en) 2011-05-02 2012-04-30 Amorphous solid salts

Publications (2)

Publication Number Publication Date
NZ617351A NZ617351A (en) 2015-09-25
NZ617351B2 true NZ617351B2 (en) 2016-01-06

Family

ID=

Similar Documents

Publication Publication Date Title
EP2705027B1 (en) Amorphous solid salts of Cobicistat (GS-9350)
AU2014221210B2 (en) The use of solid carrier particles to improve the processability of a pharmaceutical agent
US20150004239A1 (en) Pharmaceutical compositions and methods for their preparation
JP2011508778A5 (en)
JP2014169338A (en) Inhibitors of cytochrome P450
US20150045366A1 (en) Spray dried formulations
NZ617351B2 (en) Amorphous solid salts of cobicistat (gs-9350)